US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

48.21

+0.59001.24%

Pre-market: 48.750.5400+1.12%07:29 EDT

Volume:252.69K

Turnover:12.19M

Market Cap:1.56B

PE:-16.13

High:49.06

Open:47.88

Low:46.83

Close:47.62

52wk High:49.97

52wk Low:13.36

Shares:32.26M

Float Shares:21.62M

Volume Ratio:0.91

T/O Rate:1.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9880

EPS(LYR):-3.1329

ROE:-50.00%

ROA:-29.98%

PB:4.68

PE(LYR):-15.39

Loading ...

Overview Company News Filings

LB Pharmaceuticals price target raised to $69 from $45 at Clear Street

Lb Pharmaceuticals Inc : Stifel Raises Target Price to $53 from $40

THOMSON REUTERS

Craig-Hallum Remains a Buy on LB Pharmaceuticals, Inc. (LBRX)

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Lb Pharmaceuticals Inc : Leerink Partners Raises Target Price to $55 from $40

THOMSON REUTERS

Sellas Life Sciences Q2 Net Loss Widens on Higher Expenses

Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs

TherapeuticsMD Q2 License Revenue Falls; Continues to Evaluate Strategic Alternatives

LB Pharmaceuticals Q2 Loss Per Share Narrows

MT Newswires Live

Achieve Life Sciences Q2 Loss Widens on Warrant Liabilities

Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss

MT Newswires Live

LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate

Benzinga Earnings

LB Pharmaceuticals Q2 FY26 Net Loss Widens to $51.6 Million

Lb Pharmaceuticals Inc Q2 Basic EPS USD -1.71

THOMSON REUTERS

Lb Pharmaceuticals Inc Q2 Pretax Profit USD -51.603 Million

THOMSON REUTERS

Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals management to meet with Piper Sandler

LB Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

LB Pharmaceuticals Prices USD 150 Million Private Placement at USD 34.94 Per Share

Lb Pharmaceuticals - Net Proceeds to Fund Lb-102 Pipeline Expansion and General Corporate Purposes

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LBRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":48.21,"timestamp":1787601600000,"preClose":47.62,"halted":0,"volume":252689,"hourTrading":{"tag":"盘前","latestPrice":48.75,"preClose":48.21,"latestTime":"07:29 EDT","volume":4,"amount":194.5,"timestamp":1787657351748,"change":0.54,"changeRate":0.011201,"amplitude":0.005186},"delay":0,"changeRate":0.012389752204955973,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"Pre-Mkt","change":0.59,"latestTime":"08-25 07:51:30 EDT","open":47.88,"high":49.06,"low":46.83,"amount":12194947.011544,"amplitude":0.046829,"askPrice":59.7,"askSize":100,"bidPrice":48.18,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":48.21,"preHourTrading":{"tag":"盘前","latestPrice":48.75,"preClose":48.21,"latestTime":"07:29 EDT","volume":4,"amount":194.5,"timestamp":1787657351748,"change":0.54,"changeRate":0.011201,"amplitude":0.005186},"postHourTrading":{"tag":"盘后","latestPrice":48.21,"preClose":48.21,"latestTime":"19:30 EDT","volume":1229,"amount":59262.11,"timestamp":1787614207179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9123809016192315,"impliedVol":0.8171,"impliedVolPercentile":0.85},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":21621800,"roa":"-29.98%","roe":"-50.00%","lyrEps":-3.132945,"volumeRatio":0.9123809016192315,"shares":32259175,"dividePrice":0,"high":49.06,"amplitude":0.046829,"preClose":47.62,"low":46.83,"week52Low":13.36,"pbRate":"4.68","week52High":49.97,"institutionHeld":0,"latestPrice":48.21,"committee":-0.980198,"eps":-2.988,"divideRate":0,"volume":252689,"delay":0,"ttmEps":-2.988,"open":47.88,"prevYearClose":22.26,"prevWeekClose":47.62,"prevMonthClose":40.08,"prevQuarterClose":32.455,"fiveDayClose":46.23,"twentyDayClose":34.78,"sixtyDayClose":27.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LBRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.84,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.71},{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1784779200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-08-24","current":-16.134538,"percent":0.797468,"low":-37.407457,"twenty":-31.993865,"median":-24.857779,"eighty":-17.84015,"high":-0.410019,"avg":-24.312143,"sd":7.577604,"marketCap":1536181913},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-15","current":-23.123601,"twenty":-32.316764,"median":-26.760218,"eighty":-12.583143,"marketCap":900733639},{"date":"2026-05-22","current":-20.613207,"twenty":-32.30331,"median":-26.667619,"eighty":-12.598395,"marketCap":802946256},{"date":"2026-05-29","current":-20.2672,"twenty":-32.30331,"median":-26.565134,"eighty":-12.6289,"marketCap":789468229},{"date":"2026-06-05","current":-21.275774,"twenty":-32.281784,"median":-26.235508,"eighty":-12.715838,"marketCap":828755242},{"date":"2026-06-12","current":-21.010748,"twenty":-32.254875,"median":-25.973152,"eighty":-12.741767,"marketCap":818431648},{"date":"2026-06-18","current":-22.122388,"twenty":-32.201059,"median":-25.758446,"eighty":-12.784474,"marketCap":861733392},{"date":"2026-06-26","current":-22.821765,"twenty":-32.168769,"median":-25.603165,"eighty":-13.037355,"marketCap":888976212},{"date":"2026-07-02","current":-23.476971,"twenty":-32.141861,"median":-25.394457,"eighty":-14.887526,"marketCap":914498432},{"date":"2026-07-10","current":-24.838915,"twenty":-32.079972,"median":-25.197689,"eighty":-17.661739,"marketCap":967550238},{"date":"2026-07-17","current":-22.519929,"twenty":-32.026155,"median":-24.876643,"eighty":-18.127213,"marketCap":877218784},{"date":"2026-07-24","current":-25.486758,"twenty":-31.993865,"median":-24.857779,"eighty":-18.396949,"marketCap":992785692},{"date":"2026-07-31","current":-30.110006,"twenty":-31.988483,"median":-25.029051,"eighty":-18.623718,"marketCap":1172875066},{"date":"2026-08-07","current":-35.46944,"twenty":-32.036919,"median":-25.243817,"eighty":-19.236335,"marketCap":1381641093},{"date":"2026-08-14","current":-16.667021,"twenty":-32.036919,"median":-25.197689,"eighty":-18.062763,"marketCap":1428113677},{"date":"2026-08-21","current":-17.781418,"twenty":-31.993865,"median":-24.876643,"eighty":-17.822455,"marketCap":1523600835},{"date":"2026-08-24","current":-17.928248,"twenty":-31.993865,"median":-24.857779,"eighty":-17.84015,"marketCap":1536181913}],"updateTime":1787655945225},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661323298","title":"LB Pharmaceuticals price target raised to $69 from $45 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2661323298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661323298?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:15","pubTimestamp":1787256916,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman raised the firm’s price target on LB Pharmaceuticals (LBRX) to $69 from $45 and keeps a Buy rating on the share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-price-target-raised-to-69-from-45-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-price-target-raised-to-69-from-45-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659598441","title":"Lb Pharmaceuticals Inc : Stifel Raises Target Price to $53 from $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2659598441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659598441?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:20","pubTimestamp":1786620019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1BM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990840","title":"Craig-Hallum Remains a Buy on LB Pharmaceuticals, Inc. (LBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990840","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990840?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:36","pubTimestamp":1786541770,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Adam Vogel maintained a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $45.00. Vogel covers the Health...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-lb-pharmaceuticals-inc-lbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","BK4213","LBRX","BK4007","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658276289","title":"U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658276289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658276289?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:07","pubTimestamp":1786522040,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public StorageAug 12 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inclu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4490GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACM","TGT","LENZ","MNST","SR","RPD","MDLN","CVS","BLCK","FXU","MAA","GDX","BCAX","BBIO","HD","JAZZ","CUBE","CRCL","CAVA","ACVA","LOW","HLIO","LITE","LEGN","NTRA","FLUT","EXR","COAG","RSPS","LBRX","GAP","PSA","REZ","AMBQ","AUAU","CAH","TXG","MRCY","CRWV","ODDZ","LPTH","PNW","SGMT","EGGY","JBIO","NEM","ARKG","CANC","ANF","LAZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928106","title":"Lb Pharmaceuticals Inc : Leerink Partners Raises Target Price to $55 from $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928106?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:37","pubTimestamp":1786505856,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4481AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658438799","title":"Sellas Life Sciences Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2658438799","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658438799?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:13","pubTimestamp":1786479212,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Q2 net loss widens on higher expensesOverviewUS biopharma firm's Q2 net loss widened yr/yr as operating expenses increasedCompany ended Q2 with $138.3 mln in cash and cash equival","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","OLMA","BK4139","BK4007","IMNN","SLS","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948040","title":"Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948040","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948040?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:10","pubTimestamp":1786479023,"startTime":"0","endTime":"0","summary":"Inhibikase Q2 net loss widens on higher R&D, SG&A costsOverviewU.S. clinical-stage pharma's Q2 net loss widened yr/yr on higher R&D and SG&A costsCompany raised $50 mln in July via share sale to RA Ca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGMT","BK4139","LBRX","IKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948753","title":"TherapeuticsMD Q2 License Revenue Falls; Continues to Evaluate Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948753","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948753?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:09","pubTimestamp":1786478962,"startTime":"0","endTime":"0","summary":"TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternativesOverviewUS pharmaceutical royalty company's Q2 license revenue declined yr/yr due to lower licensed product salesNe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENTA","LBRX","BK4007","BK4198","TXMD","XTNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658186299","title":"LB Pharmaceuticals Q2 Loss Per Share Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2658186299","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658186299?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:40","pubTimestamp":1786452000,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals  reported Tuesday that its Q2 net loss per share narrowed to $1.71, from a loss of $13.58 per share a year earlier.Analysts polled by FactSet expected a loss of $0.80 per share.As of June 30, the company had $327.8 million in cash, cash equivalents and marketable securities.It said this balance excludes net proceeds from a $150 million private placement completed in July and, based on its current operating assumptions, expects to fund operations beyond Q2 2029.The company's net loss widened to $51.6 million from $4.9 million a year earlier, as research and development expenses rose sharply, primarily due to its Phase 3 schizophrenia trial.LB Pharmaceuticals also said it now expects topline data from that trial in the first half of 2027, earlier than previously forecast.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4213","BK4007","LB","LBRX","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658791868","title":"Achieve Life Sciences Q2 Loss Widens on Warrant Liabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2658791868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658791868?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:39","pubTimestamp":1786451965,"startTime":"0","endTime":"0","summary":"Achieve Life Sciences Q2 loss widens on warrant liabilitiesOverviewUS specialty pharma firm's Q2 net loss and loss per share missed analyst expectationsQ2 net loss includes $48.7 mln non-cash charge f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMO","LU1854104046.USD","LU0096362180.USD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0234572021.USD","LU0957791311.USD","BK4585","LU1670628061.USD","SCYX","LU1815333072.USD","LU1923621640.USD","LU2764262908.HKD","LU1153585028.USD","FMED","LU1057294990.SGD","LU1720051108.HKD","LU1623119135.USD","LU0823416689.USD","LBRX","IE00B19Z8W00.USD","LU0342679015.USD","LU0640476718.USD","LU2125909247.SGD","IE00B1BXHZ80.USD","LU2764263039.SGD","IE0009355771.USD","IE00BQXX3D17.EUR","LU0528227936.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1803068623.USD","LU2264538146.SGD","BK4548","HRTS","LU0122379950.USD","LU2063271972.USD","LU0208291251.USD","BK4121","LU0882574055.USD","IE00BQXX3C00.GBP","LU1633808545.USD","LU2468319806.SGD","GNMX","LU2543165471.USD","LU1712237335.SGD","LU1061106388.HKD","TMED","LU2041044095.USD","ACHV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658909169","title":"Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658909169","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658909169?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:09","pubTimestamp":1786450182,"startTime":"0","endTime":"0","summary":"Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990574","title":"LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990574","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990574?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:05","pubTimestamp":1786449920,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61105422/lb-pharmaceuticals-q2-eps-1-71-misses-0-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399087","title":"LB Pharmaceuticals Q2 FY26 Net Loss Widens to $51.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399087","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658399087?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:02","pubTimestamp":1786449776,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Q2 FY26 net loss widens to $51.6 millionLB Pharmaceuticals posted a Q2 net loss of USD 51.6 million, widening from USD 4.9 million a year earlier.R&D costs climbed to USD 44.1 milli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8jr1Jr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","LBRX","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD","BK4112","SG9999014005.SGD","BCDF","BK4585","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997706","title":"Lb Pharmaceuticals Inc Q2 Basic EPS USD -1.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997706?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX2ZR14F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997047","title":"Lb Pharmaceuticals Inc Q2 Pretax Profit USD -51.603 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997047?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX2ZR14F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990834","title":"Press Release: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990834","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990834?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"evaluating the efficacy and safety of LB-102 in patients with acute. Company expects to schedule a pre-NDA meeting with the FDA thereafter in. -- The 52-week open-label safety and tolerability trial , evaluating. the long-term safety and tolerability of LB-102 in patients with stable. schizophrenia, is enrolling eligible patients who have c","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","LBRX","BK4007","BK4233","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956102","title":"LB Pharmaceuticals management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956102?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:00","pubTimestamp":1786392021,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on August 17 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-management-to-meet-with-piper-sandler-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-management-to-meet-with-piper-sandler-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4233","LBRX","BK4007","LB","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656024378","title":"LB Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2656024378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656024378?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:42","pubTimestamp":1785753720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655886045","title":"LB Pharmaceuticals Prices USD 150 Million Private Placement at USD 34.94 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2655886045","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655886045?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:20","pubTimestamp":1785327655,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per shareLB Pharmaceuticals priced a USD 150 million private placement of common stock and pre-funded warrants with institution","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL74y1xn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867089","title":"Lb Pharmaceuticals - Net Proceeds to Fund Lb-102 Pipeline Expansion and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655867089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:00","pubTimestamp":1785326402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA6VXJQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}]}}